Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Kraig Biocraft Laboratories Spring Spider Silk Production Trials Exceed Expectations
GlobeNewswire
ANN ARBOR, Mich., May 09, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (KBLB.NaE) ("the Company" or "Kraig Labs"), announces today that the spring production trials of the Company's new BAM-1 hybrid parental strains have concluded, exceeding all expectations for scale, performance and robustness.
Kraig Labs reports that the spring production trials were an unabashed success. These trials proved that the Company's BAM-1 recombinant spider silk hybrids are ready for rapid production expansion. Simply stated, this has been the most fruitful and successful production cycle in the Company's history.
Renowned sericulture expert and Kraig Labs executive consultant, Dr. Nirmal Kumar, oversaw the production cycle from start to finish, including rearing and selective breeding. Careful and meticulous testing throughout the entire production trial demonstrated that the BAM-1 parental lines were the strongest and most resilient lines Kraig Labs has ever developed.
Observation and screening conducted throughout all phases of production exceeded all expectations for health and vigor within the colony. Not a single instance of disease or infection was detected at any point during the entire cycle. This result surprised local silkworm experts observing the trials. Working with mundane silkworms, they had never experienced an entire production cycle from egg to egg without any disease in a batch of thousands of silkworms.
Under the guidance of Dr. Nirmal Kumar and through a meticulous, statistically-based selective breeding protocol, the parental strains for the BAM-1 hybrid were further optimized during the production cycle. The enhancements to the parental lines from this careful breeding program were designed to deliver larger cocoons with improved reeling characteristics and higher yields.
"I am proud of the work accomplished and very impressed by the performance of the BAM-1 silkworm lines," Dr. Nirmal Kumar, stated. "The luster of the BAM-1 silk is very unique and desirable. When paired with its strength, we have created a silk that can't be matched. The results of these trials exceeded our expectations. We are now on a solid foundation to scale production of the BAM-1 hybrid to metric ton levels."
"The BAM-1 parental lines have proven to be the strongest and most resilient we have ever fielded," said Company founder and CEO, Kim Thompson. "This production run greatly exceeded our targets and has prepared us for the next phase of our business plan. With these production trials successfully concluded, we are now aggressively implementing the next phase of our business plan, which will expand our operations and target multiple production locations in multiple countries."
Thompson and Dr. Nirmal Kumar have spent the last two months directly overseeing these trials, selecting facilities for expansion, reviewing operational protocols, and meeting with officials and business leaders regarding the Company's immediate plans. Thompson is now returning to the U.S. to enact the next stages of its spider silk production expansion plan and complete the Company's transition from a technology developer to a large-scale spider silk manufacturer.
Thompson and Dr. Nirmal Kumar have spent the last two months directly overseeing these trials, selecting facilities for expansion, reviewing operational protocols, and meeting with officials and business leaders regarding the Company's immediate plans. Thompson is now returning to the U.S. to enact the next stages of its spider silk production expansion plan and complete the Company's transition from a technology developer to a large-scale spider silk manufacturer.
The BAM-1 parental lines have proven to be the strongest and most resilient we have ever fielded," said Company founder and CEO, Kim Thompson. "This production run greatly exceeded our targets and has prepared us for the next phase of our business plan. With these production trials successfully concluded, we are now aggressively implementing the next phase of our business plan, which will expand our operations and target multiple production locations in multiple countries."
"I am proud of the work accomplished and very impressed by the performance of the BAM-1 silkworm lines," Dr. Nirmal Kumar, stated. "The luster of the BAM-1 silk is very unique and desirable. When paired with its strength, we have created a silk that can't be matched. The results of these trials exceeded our expectations.
New pr out. The company just shifted a gear up.
Is DRCR taking bets on the Super Bowl?
What does this company do?
Do you have a link?
What did I miss today. I don’t look at kblb that often anymore.
Why did the company buy gold to begin with
People are trying to suppress survivin with small peptides
— Dr. Thomas Ichim (@exosome) November 18, 2022
Obviously $rgbp ‘s mRNA vaccine based approach is better because of induction of immunological memory so that the #cancer doesn’t come back https://t.co/cSh1GM2uqx
Interesting.
So if we lock up our shares what stops them from just diluting and making us just stuck out of our shares?
What will the preferred share open that day?
I was out yesterday what happened?
Can we sell the company if Oncology Pharma has the rights to some of the patents?
Just to show that other companies besides big pharmaceutical are in the game.
Amazon launches cancer vaccine clinical trial in partnership with Fred Hutchinson
Amazon is working with the Fred Hutchinson Cancer Research Center to develop cancer vaccines, according to a filing.
Amazon is listed as a collaborator on a filing for an FDA-approved clinical trial, which seeks to develop personalized vaccines to treat breast and skin cancers.
Video out
Video out
Gives me a chance to get more shares
Maybe the upcoming video will tell us more.
From twitter page. Hopefully just the beginning
We are pleased to have signed our latest deal in Dubai on the eve of Eid al-Adha. We look forward to reporting more later. Great work from the $ILUS and $WSFT team.
We are pleased to have signed our latest deal in Dubai on the eve of Eid al-Adha. We look forward to reporting more later. Great work from the $ILUS and $WSFT team.
Along with our ability to cut down on diseases we should be selling the ability to make larger cocoons to the regular silk market. Easy revenue.
No need to be like that. We have the same goal.
That wasn’t advice. It was a request.
Quote from the company
Next time it runs can you hold off from selling your millions of shares so it won’t kill the run?
News tomorrow would be nice. Question is, do we have to have the name change before they announce the big acquisition?
People were expecting news and when it didn’t come today they moved on to a different play. This is the otc.
How can you say that?
We were told it is coming and these guys don’t play otc games if you haven’t noticed
Getting ready for some news